

# Testis

**Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies.**

---

*Protocol revision date: January 2005  
Based on AJCC/UICC TNM, 6<sup>th</sup> edition*

## Procedures

- **Radical Orchiectomy**
- **Retroperitoneal Lymphadenectomy (RPLND)**

## Authors

Mahul B. Amin, MD

Department of Pathology, Emory University Hospital, Atlanta, Georgia

John R. Srigley, MD

Department of Laboratory Medicine, Credit Valley Hospital, Mississauga, Ontario, Canada

Thomas M. Ulbright, MD

Department of Pathology, Indiana University Hospital, Indianapolis, Indiana

For the Members of the Cancer Committee, College of American Pathologists

**Previous contributors:** Richard S. Foster, MD; Patrick J. Loehrer, MD; Judd W. Moul, MD; Jae Y. Ro, MD; Robert E. Scully, MD; Gillian M. Thomas, MD

© 2005. College of American Pathologists. All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary (Checklist)" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

## **Summary of Changes to Checklist(s)**

*Protocol revision date: January 2005*

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

**Surgical Pathology Cancer Case Summary (Checklist)**

*Protocol revision date: January 2005  
Applies to invasive cancers only  
Based on AJCC/UICC TNM, 6<sup>th</sup> edition*

**TESTIS: Radical Orchiectomy**

Patient name:

Surgical pathology number:

<b>Note: Check 1 response unless otherwise indicated.</b>
---

**\*Serum Tumor Markers (check all that apply)**

(see optional Serum Tumor Markers Classification [S] in Microscopic section)

- \*  Unknown
- \*  Serum marker studies within normal limits
- \*  Alpha-fetoprotein (AFP) elevation
- \*  Beta-subunit of human chorionic gonadotropin (b-hCG) elevation
- \*  Lactate dehydrogenase (LDH) elevation

**MACROSCOPIC****Laterality**

- Right
- Left
- Both
- Not specified

**Focality**

- Unifocal
- Multifocal

**Tumor Size**

Greatest dimension of main tumor mass: \_\_\_ cm

\*Additional dimensions: \_\_\_ x \_\_\_ cm

Greatest dimensions of additional tumor nodules: \_\_\_ cm, \_\_\_ cm, etc

 Cannot be determined (see Comment)

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**MICROSCOPIC****Histologic Type**

- Intratubular germ cell neoplasm, unclassified only  
 Seminoma, classic type  
 Seminoma with syncytiotrophoblastic cells  
 Mixed germ cell tumor (specify components and percentages):  
 \_\_\_\_\_  
 \_\_\_\_\_  
 Embryonal carcinoma  
 Yolk sac tumor  
 Choriocarcinoma, biphasic  
 Choriocarcinoma, monophasic  
 Placental site trophoblastic tumor  
 Mature teratoma  
 Immature teratoma  
 Teratoma with a secondary malignant component  
 (specify type): \_\_\_\_\_  
 Monodermal teratoma, carcinoid  
 Monodermal teratoma, primitive neuroectodermal tumor  
 Monodermal teratoma, other (specify): \_\_\_\_\_  
 Polyembryoma  
 Diffuse embryoma  
 Spermatocytic seminoma  
 Spermatocytic seminoma with a sarcomatous component  
 Testicular scar  
 Mixed germ cell-sex cord-stromal tumor, gonadoblastoma  
 Mixed germ cell-sex cord-stromal tumor, others  
 (specify): \_\_\_\_\_  
 Other (specify): \_\_\_\_\_  
 Malignant neoplasm, type cannot be determined

**Pathologic Staging (pTNM)**Primary Tumor (pT)

- pTX: Cannot be assessed  
 pT0: No evidence of primary tumor  
 pTis: Intratubular germ cell neoplasia only (carcinoma in situ)  
 pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion  
 (tumor may invade tunica albuginea but not tunica vaginalis)  
 pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion or  
 tumor extending through tunica albuginea with involvement of tunica vaginalis  
 pT3: Tumor invades spermatic cord with or without vascular/lymphatic invasion  
 pT4: Tumor invades scrotum with or without vascular/lymphatic invasion

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Regional Lymph Nodes (pN)

- pNX: Cannot be assessed
  - pN0: No regional lymph node metastasis
  - pN1: Metastasis with a lymph node mass less than 2 cm in greatest dimension and 5 or fewer positive nodes, none more than 2 cm in greatest dimension
  - pN2: Metastasis with a lymph node mass greater than 2 cm but not more than 5 cm in greatest dimension, or more than 5 nodes positive, none greater than 5 cm; or evidence of extranodal extension of tumor
  - pN3: Metastasis with a lymph node mass greater than 5 cm in greatest dimension
- Specify: Number examined:   
 Number involved:

Distant Metastasis (pM)

- pMX: Cannot be assessed
- pM1: Distant metastasis present
- pM1a: Non-regional lymph nodes or pulmonary metastasis
- pM1b: Distant metastasis other than to non-regional lymph nodes and lungs  
 \*Specify site(s), if known:

**\*Serum Tumor Markers (S)**

- \*  SX: Serum marker studies not available or performed
  - \*  S0: Serum marker study levels within normal limits
- |                                | <u>LDH</u>  |     | <u>HCG (mIU/mL)</u> |     | <u>AFP (ng/mL)</u> |
|--------------------------------|-------------|-----|---------------------|-----|--------------------|
| * <input type="checkbox"/> S1: | <1.5 x nl   | and | <5,000              | and | <1,000             |
| * <input type="checkbox"/> S2: | 1.5-10 x nl | or  | 5,000-50,000        | or  | 1,000-10,000       |
| * <input type="checkbox"/> S3: | >10 x nl    | or  | >50,000             | or  | >10,000            |

**Margins (check all that apply)**

Spermatic Cord Margin

- Cannot be assessed
- Uninvolved by tumor
- Involved by tumor

Other Margin(s)

- Cannot be assessed
- Uninvolved by tumor (specify):
- Involved by tumor (specify):
- Not applicable

**Direct Extension of Invasive Tumor (check all that apply)**

- \*  Rete testis
- \*  Epididymis
- Peri-hilar fat
- Spermatic cord
- Tunica vaginalis
- Scrotal wall
- None of the above

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)**

- Absent
- Present
- Indeterminate

**\*Additional Pathologic Findings (check all that apply)**

- \*  None identified
- \*  Intratubular germ cell neoplasia
- \*  Hemosiderin-laden macrophages
- \*  Atrophy
- \*  Other (specify): \_\_\_\_\_

**\*Comment(s)**

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Surgical Pathology Cancer Case Summary (Checklist)***Protocol revision date: January 2005**Applies to invasive cancers only**Based on AJCC/UICC TNM, 6<sup>th</sup> edition***TESTIS: Retroperitoneal Lymphadenectomy**

Patient name:

Surgical pathology number:

**Note: Check 1 response unless otherwise indicated.****\*Prelymphadenectomy Treatment**

- \*  Chemo/radiation therapy
- \*  No chemo/radiation therapy
- \*  Unknown

**\*Serum Tumor Markers (check all that apply)**

- \*  Unknown
- \*  Serum marker studies within normal limits
- \*  Alpha-fetoprotein (AFP) elevation
- \*  Beta subunit of human chorionic gonadotropin (b-hCG) elevation
- \*  Lactate dehydrogenase (LDH) elevation

**MACROSCOPIC****\*Specimen Site(s)**

\*Specify: \_\_\_\_\_

**\*Number of Nodal Groups Present**

- \*Specify:
- \*  Cannot be determined

**Size of Largest Metastasis**Greatest dimension:  cm\*Additional dimensions:  x  cm**MICROSCOPIC****Viability of Tumor (if applicable)**

- Viable tumor present
- Non viable tumor present
- No tumor present

8

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Histologic Type of Metastatic Tumor**

- Seminoma, classic type  
 Seminoma with syncytiotrophoblastic cells  
 Mixed germ cell tumor (specify components and percentages):  
 \_\_\_\_\_  
 \_\_\_\_\_  
 Embryonal carcinoma  
 Yolk sac tumor  
 Choriocarcinoma, biphasic  
 Choriocarcinoma, monophasic  
 Placental site trophoblastic tumor  
 Mature teratoma  
 Immature teratoma  
 Teratoma with a secondary malignant component  
 (specify type): \_\_\_\_\_  
 Monodermal teratoma, carcinoid  
 Monodermal teratoma, primitive neuroectodermal tumor  
 Polyembryoma  
 Diffuse embryoma  
 Spermatocytic seminoma  
 Spermatocytic seminoma with a sarcomatous component  
 Other (specify): \_\_\_\_\_  
 Malignant neoplasm, type cannot be determined

**Regional Lymph Nodes (pN)**

- pNX: Cannot be assessed  
 pN0: No regional lymph node metastasis  
 pN1: Metastasis with a lymph node mass less than 2 cm in greatest dimension and 5 or fewer positive nodes, none greater than 2 cm in greatest dimension  
 pN2: Metastasis with a lymph node mass greater than 2 cm but no more than 5 cm in greatest dimension, or more than 5 nodes positive, none greater than 5 cm; or evidence of extranodal extension of tumor  
 pN3: Metastasis in a lymph node greater than 5 cm in greatest dimension  
 Specify: Total number examined: \_\_\_\_  
 Total number involved: \_\_\_\_

**Nonregional Lymph Node Metastasis (M1a)**

- Not applicable  
 Absent  
 Present

**\*Comment(s)**

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.